2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 353-355
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Biological Processes, Immune Mechanism, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

1059 Post-transplant cyclophosphamide or standard graft-versus-host disease prophylaxis for T-cell lymphoma patients undergoing allogeneic hematopoietic cell transplantation: A registry study from the EBMT lymphoma working party

Nina Malburg, Mathilde Fekom, PhD2, Raynier Devillier, PhD3, Edouard Forcade, MD, PhD4, Peter Dreger, Prof. Dr. med.5, Jonathan Bordat, MD6, Francis Ayuketang Ayuk, MD7, Matthias Stelljes8, Georg Lenz, MD9, Jan Vydra10, Patrice Chevallier11, Katherine Clesham12, Johannes Schetelig13, Anna Maria Sureda Balari, MD,PhD14, Gandhi Damaj, MD, PhD15, Norbert Schmitz16, Ali Bazarbachi17
1 University hospital Muenster, Münster, Germany
2 European Society for Blood and Marrow Transplantation (EBMT), Paris, France
3 Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Maseille, France
4 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
5 University of Heidelberg, Heidelberg, Germany
6 Saint-Louis Hospital, Paris, France
7 University Hospital Eppendorf, Hamburg, Germany
8 University hospital Muenster, Münster, Germany
9 University hospital Muenster, Münster, Germany
10 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
11 CHU Nantes, Nantes, France
12 University College London Hospital, London, United Kingdom
13 Universitätsklinikum Dresden, Dresden, Germany
14 Institut Català d'Oncologia-L'Hospitalet, Instituto de Investigación Biomédica de Bellvitge, Universitat de Barcelona, Barcelona, Spain
15 University of Caen, CNRS, ISTCT UMR6030, GIP Cyceron, Caen, France
16 University hospital Muenster, Münster, Germany
17 American University of Beirut, Beirut, Lebanon

Background: In myeloid malignancies, prospective trials and retrospective analyses showed that post-transplant cyclophosphamide (PTCy) used for graft-versus-host disease (GvHD) prophylaxis after haploidentical allogeneic hematopoietic cell transplantation (allo-HCT), but also in patients (pts) with matched related and unrelated donors (MRD, MUD), can improve GvHD-free, relapse-free survival (GRFS). Progression-free survival (PFS) and overall survival (OS) have mostly been similar to standard GvHD prophylaxis. In pts with relapsed/refractory T-cell lymphoma, retrospective analyses suggested that PTCy after haploidentical transplantation results in survival rates comparable to those observed after MRD and MUD transplants with standard GvHD prophylaxis. Data on PTCy-based GvHD prophylaxis in MRD and MUD transplants for T-cell lymphoma have not been reported. We therefore analysed outcomes after MRD and MUD transplants, focusing on GvHD as well as the graft-versus-lymphoma (GvL)-effect being particularly strong in pts with T-cell lymphoma.

Methods: This retrospective European Society for Blood and Marrow Transplantation (EBMT) study compared PTCy-based GvHD prophylaxis with standard calcineurin inhibitor-based prophylaxis in adults with T-cell lymphoma undergoing first allo-HCT from MRD, MUD, or mismatched related donors (MMRD). Primary endpoint was GRFS; secondary endpoints included PFS, OS, relapse incidence (RI), non-relapse mortality (NRM), acute and chronic GvHD (cGVHD). The study included 2,539 adults (median age 53 years, 33% female) treated between 2010 and 2024 comprising 1,025 MUD transplants (129 PTCy, 896 non-PTCy), 955 MRD transplants (74 PTCy, 881 non-PTCy), and 559 MMRD transplants (482 PTCy, 77 non-PTCy). Eligible entities included PTCL NOS, AITL, intestinal T- and NK-cell lymphomas, hepatosplenic T-cell lymphoma, and ALCL, both ALK-pos. and -neg. Pre-planned subgroup analyses evaluated the role of donor type, conditioning intensity, and disease status at transplant. To reduce baseline imbalances between PTCy and standard prophylaxis groups, a propensity score–matched analysis was performed based on relevant clinical covariates.

Results: After PTCy-based GvHD prophylaxis, 1-year GRFS of pts after MRD, MUD, and MMRD transplants were 28.8%, 34.4% and 26.0%, comparable to standard prophylaxis (MRD p=0.8; MUD p=0.8; MMRD p=0.9). In MRD transplants, 1-year OS and PFS were 67.0% and 57.4% after PTCy; OS, PFS, RI, and NRM were not significantly different after PTCy or standard prophylaxis (OS p=0.5; PFS p=0.6; RI p=0.9; NRM p=0.7). Acute GvHD grades II–IV and III–IV were similar (p=0.7 and p=0.5); cGvHD overall showed no significant difference (p=0.2), but extensive cGvHD was significantly lower with PTCy (p=0.028). In MUD transplants, 1-year OS and PFS were 72.3% and 64.7% after PTCy; OS, PFS, RI, and NRM were also comparable (OS p=0.7; PFS p>0.9; RI p=0.7; NRM p=0.7). Acute GvHD grades II–IV and III–IV did not differ (p=0.3 and p>0.9); cGvHD was significantly lower with PTCy (p=0.009), extensive cGvHD was not significantly different (p=0.3). In MMRD transplants, 1-year OS and PFS were 66.5% and 60.0% after PTCy; OS, PFS, RI, and NRM were also similar after PTCy or standard prophylaxis, acute GvHD, grades II–IV and III–IV, as well as overall and extensive cGvHD, did not differ significantly (p=0.3, p=0.6, p=0.6, p=0.2). Conditioning (myeloablative vs. reduced intensity) had no significant impact on OS, PFS, RI, NRM, GRFS, or GvHD in MRD and MUD transplants. By contrast, disease status at transplantation was strongly prognostic: pts in CR/PR had significantly better GRFS, OS, PFS, and lower RI (p<0.001), with lower 1-year NRM of 15.6% in MRD and 12.6% in MUD compared to pts not in CR/PR (MRD p=0.009; MUD p=0.031).

Conclusion: PTCy-based prophylaxis provides outcomes comparable to standard GvHD prophylaxis in T-cell lymphoma pts allografted from MRD, MUD, and MMRD; cGvHD was lower in pts transplanted from MRD and MUD, but RI was not significantly affected. Disease status at transplantation remains the major determinant of relapse rates and survival. These findings support the use of PTCy for GvHD prophylaxis in all pts with T-cell lymphoma undergoing allo-HCT from any donor type, while preserving disease control.

Nina Malburg: No relevant conflicts of interest to declare.